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Abstract
The liver possesses distinct tolerogenic properties because of continuous exposure to bacterial constituents and
nonpathogenic food antigen. The central immune mediators required for the generation of effective immune responses in
the liver environment have not been fully elucidated. In this report, we demonstrate that the liver can indeed support
effector CD8
+ T cells during adenovirus infection when the T cells are primed in secondary lymphoid tissues. In contrast,
when viral antigen is delivered predominantly to the liver via intravenous (IV) adenovirus infection, intrahepatic CD8
+ T cells
are significantly impaired in their ability to produce inflammatory cytokines and lyse target cells. Additionally, intrahepatic
CD8
+ T cells generated during IV adenovirus infection express elevated levels of PD-1. Notably, lower doses of adenovirus
infection do not rescue the impaired effector function of intrahepatic CD8
+ T cell responses. Instead, intrahepatic antigen
recognition limits the generation of potent anti-viral responses at both priming and effector stages of the CD8
+ T cell
response and accounts for the dysfunctional CD8
+ T cell response observed during IV adenovirus infection. These results
also implicate that manipulation of antigen delivery will facilitate the design of improved vaccination strategies to persistent
viral infection.
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Introduction
The liver is a site for continual exposure to bacterial constituents
and food antigens. To prevent the generation of harmful immune
responses against bacteria or innocuous food antigens, the liver
evolves a way to dampen host immunity [1]. The tolerogenic
nature of the liver is manifested by the high success rate of liver
transplantation such that Iiver transplantation across MHC class I
mismatches allows for successful acceptance of allografts [2,3,4]. In
addition, the liver has been reported to be involved in the
accumulation and deletion of activated CD8
+ T cells: the removal
of activated CD8
+ T cells in the liver contributes to T cell
homeostasis and the contraction of T cell responses during
infection [5,6,7]. As a result of these properties, numerous
hepatotropic infections including HCV, HBV, and malaria
establish chronic infections in the liver compartment [8,9,10].
Notably, CD8
+ T cell responses generated during viral infection in
the liver with the establishment of viral persistence display a
significant defect in effector function and become functionally
exhausted in later stages of infection [11,12]. Enhanced levels of T
cell apoptosis have also been observed during chronic liver
infection [13,14].
Paradoxically, the liver is not solely the site to induce T cell
tolerance. The liver appears to support robust effector CD8
+ T
cells responses against multiple pathogens [15,16,17]. For
example, it has recently been shown that the liver is a major
repository for effector CD8
+ T cells during influenza infection
[18,19] and T cell mediated hepatocyte damage results from the
liver infiltrating activated T cells [20,21,22]. It has been previously
reported that the liver may serve as an extralymphoid site for T
cell priming by utilizing model systems in which CD8
+ T cell
activation and priming were assessed following recognition of
allogenic MHC molecules [23,24,25]. The strong intensity of
TCR stimulation and high expression levels of MHC molecules
during allogenic T cell activation do not accurately reflect what
occurs during physiological anti-viral responses. Furthermore,
CD8
+ T cell activation can occur in the liver following recognition
of non-self antigen [26]. However, it still remains unclear if
primary T cell priming can occur in the liver following
hepatotropic viral infection and if liver cells are able to present
viral antigen and prime intrahepatic CD8
+ T cells in vivo. Studies
conducted to elucidate the immune factors involved in the effective
generation and regulation of anti-viral CD8
+ T cells to liver
infections will greatly improve treatment strategies against
persistent viral infections.
In this study, we sought out to determine the immunological
factor(s) that play a pivotal role in altering the balance between T
cell tolerance induction and immunity in the liver. We
demonstrate here that the site of initial CD8
+ T cell priming
determines the generation of effector CD8
+ T cell responses in the
liver. Numerous studies have shown that IV adenovirus infection
results in the delivery of recombinant viruses directly to the liver
[27,28,29]. Here, we report that CD8
+ T cell responses generated
during IV adenovirus infection display a functional defect in
effector cytokine production and CTL activity as observed during
persistent liver infections. Interestingly, we demonstrate here that
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+ T cell priming; however, intrahepatic
CD8
+ T cell activation is suboptimal and does not result in the
differentiation of effector CD8
+ T cells. In contrast, when
adenovirus infection of the liver is limited by delivering adenovirus
via subcutaneous (SubQ) inoculation, potent anti-viral CD8
+ T
cells are detected in the liver. During SubQ adenovirus infection,
CD8
+ T cells are activated in the inguinal lymph node and
differentiate into effector CD8
+ T cells. However, effector CD8
+ T
cells that are primed in the periphery are rapidly suppressed
following intrahepatic antigen recognition during viral infection.
These results suggest that intrahepatic antigen presentation limits
anti-viral CD8
+ T cell responses both at the priming and effector
stages of the T cell response.
Materials and Methods
Mice and Recombinant Adenovirus
Thy1.2
+ C57BL/6 mice were purchased from Taconic Farms
(Hudson, NY). Both Thy1.1
+ and OT-1 mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). Splenectomized
and sham C57BL/6 mice were purchased from Taconic Farms
(Hudson, NY). OT-1 mice were bred with Thy1.1
+ mice to
generate the Thy1.1
+OT-1
+ mice. All mice were housed in a
pathogen-free facility and were tested routinely for mouse hepatitis
virus and other pathogens. All mice were handled according to
protocols approved by the University of Virginia Institutional
Animal Care and Use Committee.
Replication-deficient recombinant adenovirus (rAd) expressing
the bgal protein under the control of the human CMV promoter
(Ad-LacZ) and lacking E1 and E3 genes was provided by Dr. Greg
Helm (University of Virginia). rAd expressing ovalbumin (Ad-
OVA) was generously provided by Dr. Timothy L. Ratliff
(University of Iowa) and the Iowa Gene Transfer Vector Core
(Iowa City, IA). Adenovirus vectors were propagated in 293A cells
and purified by two consecutive cesium chloride gradient. Mice
were injected with 5610
8,5 610
7,5 610
6,o r5 610
5 PFU of rAd
per mouse by either SubQ or IV immunization route depending
on the experiment.
Liver Leukocytes Isolation and Flow Cytometric Analysis
Intrahepatic lymphocytes (IHLs) were isolated from livers as
described previously [30]. Briefly, the liver was perfused with
PBS/0.05% collagenase (Sigma-Aldrich) and then washed with
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented
with 10% newborn calf serum (NBCS). Liver sections were finely
minced and digested further with PBS/0.05% collagenase.
Mononuclear cells were purified by nycodenz gradient centrifu-
gation. Splenocytes were prepared by mechanical disruption and
isolation over a Ficoll gradient.
PE-labeled H2-K
b bgal tetramer (ICPMYARV) was provided
by the Tetramer Core Facility of the National Institutes of Health.
APC-labeled H2-K
b OVA tetramer (SIINFEKL) was purchased
from the Baylor College of Medicine MHC Tetramer Core
Laboratory. The following reagents were used for cell surface and
intracellular staining: anti-CD8 (clone 53-6.7), anti-PD-1 (clone
J43), anti-B7-H1 (clone MIH5), anti-IFN-c (clone XMG1.2), anti-
TNFa (clone MP6-XT22), anti-CD25 (clone PC61), anti-CD69
(clone H1.2F3), anti-CD62L (clone MEL-14), anti-Thy1.1 (clone
HIS51), anti-Thy1.2 (clone 53-2.1), anti-MHC-II (clone M5/
114.15.2), and anti-CD11c (clone N418) Abs which were
purchased from eBioscience (San Diego, CA). Anti-granzyme B
(clone GB12) Ab was purchased from Caltag Laboratories
(Burlingame, CA). Anti-CD8 (clone 53-6.7) and anti-Thy1.1
(clone OX-7) Abs were purchased from BD Bioscience (San Jose,
CA). For the cell surface labeling experiments, 2610
6 splenocytes
or liver leukocytes were incubated with the corresponding Abs and
tetramer for 30 min at 4uC in staining buffer (PBS with 2% FBS
and 0.1% NaN3). After staining, cells were fixed in BD FACS
lysing solution. Flow cytometry data for each of the experiments
was acquired using a BD FACS Canto (BD Immunocytometry
Systems). Results were analyzed using FlowJo software (Tree Star
Inc., Ashland, OR).
Adoptive Transfer of TCR Transgenic T Cells
CD8
+ T cells were isolated from the spleens of Thy1.1
+OT-1
+
mice using positive magnetic bead separation (Miltenyi Biotec).
Greater than 95% of the splenic CD8
+ T cells that were isolated
from the Thy1.1
+OT-1
+ mice were specific for the OVA257–264
epitope and stained positive for OVA tetramer before adoptive
transfer (data not shown). In the experiments that were conducted
to assess T cell proliferation, purified CD8
+ T cells were labeled
with 1.8 mM CFSE, and CFSE labeled Thy1.1
+OT-1
+CD8
+ T
cells (2610
6 cells per mouse) were adoptively transferred by tail
vein injection into naı ¨ve Thy1.2
+ mice. Mice were allowed to rest
for one day and then mice were infected by either IV or SubQ
immunization route with Ad-OVA. In the experiments that
utilized splenectomized mice to ascertain liver specific priming of
CD8
+ T cells, mice were treated with Mel-14 Ab (100 mg/mouse)
by IP administration one day before adoptive transfer to limit the
entry of Thy1.1
+OT-1
+CD8
+ T cells into the LNs. To verify
efficient blockade of T cell entry into LNs following MEL-14 Ab
treatment, the presence of adoptively transferred Thy1.1
+OT-1
+
CD8
+ T cells in the inguinal lymph nodes (Ig LN) was evaluated.
For the early activation studies, purified 4610
6 Thy1.1
+OT-
1
+CD8
+ T cells were adoptively transferred by tail vein injection
into naı ¨ve Thy1.2
+ mice. Mice were allowed to rest for one day
and then were infected with Ad-OVA. Organs were harvested at
4, 6, and 24 hours post-infection (p.i.) and the expression of CD69,
CD25, and OVA tetramer by antigen-specific and endogenous
CD8
+ T cells was analyzed by flow cytometry. For the 0 hour
data, mice were treated with PBS as a control.
Ex Vivo Analysis of Ag-Specific CD8
+ T Cell Function
2610
6 splenocytes or liver leukocytes were incubated for 5 hours
in IMDM supplemented with 10% FBS, 10 U/ml penicillin G,
2 mM L-glutamine, 0.05% 2-ME, 1 mg/mL brefeldin-A (BD
Biosciences) and 2 mg/ml of either OVA (SIINFEKL) peptide or
LacZ (ICPMYARV) peptide. For the PMA/ionmycin re-stimula-
tion assay, 500 ng/mL ionomycin, 5 ng/mL PMA, and 1 mg/mL
brefeldin-A (BD Biosciences) was added to re-stimulation media
instead of peptide. After incubation, the cells were surface labeled
with anti-CD8 Ab as described earlier, followed by intracellular
staining for IFN-c, granzyme-B, and TNF-a. For the antigen
presentation assay, Thy1.2
+ C57BL/6 mice were infected with
5610
8 PFU Ad-OVA via either SubQ or IV immunization. At
48 hours p.i., liver, spleen, Ig LN, and liver LN cells were isolated
and then incubated with1610
5 naı ¨ve CFSE labeled Thy1.1
+OT-1
+
CD8
+ T cells in vitro for 72 hours.
Effect of Liver Antigen on Influencing Intrahepatic CD8
+ T
Cell Effector Function
5610
6 Thy1.1
+OT-1
+CD8
+ T cells were adoptively transferred
into Thy1.2
+ C57BL/6 mice followed by infection with 5610
8
PFU Ad-OVA via SubQ inoculation one day later. On day 4 p.i.,
spleen and Ig LN cells were isolated from these mice and Thy1.1
+
cells were purified using positive magnetic bead separation. 2610
6
Thy1.1
+OT-1
+CD8
+ T cells from day 4 SubQ primed mice were
Dysfunctional T Cell in Liver
PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7619adoptively transferred into Thy1.2
+ mice that were infected for 4
days earlier via IV inoculation with either 5610
8 PFU Ad-LacZ
(inflammation group) or 5610
8 PFU Ad-OVA (Ag+inflammation
group). As a control, 5610
6 Thy1.1
+OT-1
+CD8
+ T cells from day
4 SubQ primed mice were adoptively transferred into naı ¨ve
Thy1.2
+ mice (control group). At 24 hours post adoptive transfer,
CD8
+ T cell responses were analyzed by flow cytometry.
Generation of Bone Marrow Chimeras
C57BL/6 recipient mice were lethally irradiated (950 rad) and
were then injected IV with 5610
6 bone marrow cells from
C57BL/6 or BALB/c mice that were depleted of T cells using
magnetic bead separation (Miltenyi Biotec) according to the
manufacturer’s protocol. To limit pathogenic infection during
bone marrow reconstitution, mice were given 1 mg/ml sulfadoxin
in the drinking water during the first month. Chimeric mice were
used in experiments at least 2 months after reconstitution. The
expression of H2-K
b and H2-K
d by CD11b
+CD45
+ cells in the
liver was determined using flow cytometry to verify complete
donor chimerism.
Statistical Analysis
Student’s t tests were used to evaluate the significance of the
differences. A value of p,0.05 was regarded as statistically
significant.
Results
Reduced CD8
+ T Cell Responses Are Generated by
Intravenous Administration of Adenovirus
Secondary lymphoid tissues, e.g. lymph nodes and spleen, are
generally considered to be the major sites of activation,
proliferation, and differentiation of naı ¨ve antigen-specific CD8
+
T cells into effector cells. However, the liver has also been
implicated as a potential site of extralymphoid induction of CD8
+
T cell responses to alloantigens and hepatotropic infectious agents
including viruses. Recombinant adenoviruses (rAd) have been
demonstrated to direct expression of foreign antigens to the liver
when rAd is administered by the intravenous (IV) route. To
examine whether intrahepatic expression of foreign antigen
delivered by rAd vector would result in the activation of antigen
specific CD8
+ T cells and the subsequent development of CD8
+
effector T cells, we infected C57BL/6 mice with 5610
8 PFU of
rAd expressing the gene encoding ovalbumin (OVA) protein (Ad-
OVA) by IV route. We chose Ad-OVA to probe the CD8
+ T cell
response to the liver because this protein induces a robust CD8
+ T
cell response in this mouse strain and OVA antigen-specific T cells
from TCR transgenic mouse lines are available for more detailed
analysis on antigen-specific CD8
+ T cell responses. As a control,
we introduced the same inoculum dose of Ad-OVA by
subcutaneous (SubQ) route in order to initiate CD8
+ T cell
response through secondary lymphoid tissue presentation within
the lymph nodes draining the site of virus infection.
SubQ inoculation of virus resulted in the accumulation of a
significant number of OVA-specific tet
+ CD8
+ T cells in the liver
of inoculated mice at days 7 and 14 p.i. (Fig. 1A). Approximately
50% of OVA-specific tet
+ CD8
+ T cells in the liver produce IFN-c
in response to specific peptide stimulation in vitro (Fig. 1B). As
demonstrated below, the accumulation of these CD8
+ effector T
cells in the liver of mice with SubQ infection reflects the
activation/proliferation and differentiation of naı ¨ve antigen
specific CD8
+ T cells in the lymph nodes draining the site of
virus infection with subsequent migration of the activated cells into
the liver at later times. In contrast, the IV administration of virus
resulted in a markedly diminished OVA specific CD8
+ T cell
response in the liver as detected by tetramer staining (Fig. 1A) with
a likewise markedly diminished frequency of CD8
+ T cells
responding to specific peptide stimulation in vitro with IFN-c
production (Fig. 1B). This diminished response to IV adenovirus
delivery was not an exclusive property of the Ad-OVA. When we
carried out a corresponding comparison of the impact of IV versus
SubQ inoculation on the subsequent CD8
+ T cell response in the
liver using rAd expressing b-galactosidase (Ad-LacZ), we observed
a similar diminished CD8
+ T cell response to IV administration of
Ad-LacZ at days 7 and 14 p.i. as measured by both tetramer
staining and IFN-c production (Fig. 1C).
The finding of the reduced CD8
+ T cell response to IV virus
administration was not expected and suggested that there may be
a diminished induction of antigen specific anti-viral CD8
+ T cell
responses and/or a defective response of effector T cells generated
following IV virus administration when antigen expression is
targeted to the liver. It should be noted, however, that IV
administration of rAd has been reported to result in immunologic
tolerance although the observation is made by administration of
rAd virus at 10-100 fold higher doses than that employed in our
studies [31]. To determine if the diminished CD8
+ T cell response
observed reflected a high tolerogenic dose of virus delivered by the
IV route, we analyzed the effect for various doses of rAd virus on
the generation of CD8
+ T cell responses in the liver following IV
virus inoculation. As Fig. 1D demonstrates, the decreased dose of
virus inoculum administered by the IV route only served to reduce
the overall magnitude of CD8
+ T cell response detected in the liver
by either tetramer staining or IFN-c production.
We believe, therefore, that under the experimental conditions
employed here, the diminished CD8
+ T cell response observed in
the liver after IV virus administration was not easily attributable to
high dose tolerance based on the size of the inoculum employed.
Rather the results (along with findings presented below) suggest
that IV administration of this hepatotropic virus results in direct
priming of CD8
+ T cells in the liver with consequent alterations in
CD8
+ T cell activation and/or function. To further test the impact
of inoculum dose and route of virus administration on the
subsequent CD8
+ T cell response, we inoculated mice with 5610
8
PFU of rAd by the intranasal (IN) route and evaluated the
development of the CD8
+ T cell response in the lungs and liver
thereafter. As reported by others for virus infection in the
respiratory tract [32], virus administration at this site results in
induction of CD8
+ T cell responses exclusively in the lymph nodes
draining the respiratory tract. The IN administration of virus
which, like SubQ virus administration, restricts virus to the lymph
nodes draining the site of inoculation, results in a vigorous CD8
+ T
cell response in the liver (Fig. 1E) and lungs (data not shown).
Induction of CD8
+ T Cell Responses Can Occur in the
Liver
The IV administration of virus will not only deposit virus in the
liver but antigen can be detectable in other sites including the
secondary lymphoid tissues by migration of dendritic cells taken up
antigen. It was therefore important to demonstrate whether virus
deposition in the liver resulted in CD8
+ T cell activation in that
site and whether altered CD8
+ T cell responses in the liver could
account for the observed impaired responses observed. One
potential explanation for the finding of diminished CD8
+ T cell
responses in the liver following IV virus inoculation is that there
might be a defect in the activation and/or proliferation of naı ¨ve
CD8
+ T cells responding directly in the liver. In order to
determine if the liver could serve as a site of naı ¨ve CD8
+ T cell
activation following IV virus administration in addition to
Dysfunctional T Cell in Liver
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+ T cell responses in the liver. (A, B) C57BL/6 mice were infected
with 5610
8 PFU Ad-OVA via either SubQ or IV inoculation. At days 7 and 14 p.i., liver leukocytes were isolated and the percentage of OVA tet
+CD8
+ T
cells (A) was determined by direct ex vivo staining. The percentage of CD8
+ T cells producing IFN-c (B) was assessed following OVA peptide
restimulation for 5 hours in the presence of monensin. Data are representative of at least two independent experiments for each time point (n=3/
group). (C) C57BL/6 mice were infected with 5610
8 PFU Ad-LacZ via either SubQ or IV administration. At days 7 and 14 p.i., the percentage of bgal
tet
+CD8
+ T cells and IFN-c-producing CD8
+ T cells was determined. Data are presented as averages 6 SEM (n=3/group). (D) C57BL/6 mice were
infected with Ad-LacZ via IV inoculation at 10
8,1 0
7,1 0
6,o r1 0
5 PFU per mouse. The percentage of bgal tet
+CD8
+ T cells and IFN-c
+CD8
+ T cells in the
liver was determined at day 7 p.i. Data are representative of three independent experiments. (E) C57BL/6 mice were infected with 5610
8 PFU Ad-OVA
via SubQ, IV, or IN immunization. At 7 days p.i., the percentage of OVA tet
+CD8
+ T cells and IFN-c
+CD8
+ T cells resident in the liver was calculated.
Data are representative of two independent experiments.
doi:10.1371/journal.pone.0007619.g001
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strategy using OT-1 CD8
+ TCR transgenic T cells directed to the
OVA protein epitope displayed by the Ad-OVA virus. These
Thy1.1
+ naı ¨ve CD8
+ TCR transgenic T cells were labeled with the
dilution sensitive dye CFSE and then adoptively transferred into
congenic Thy1.2
+ recipients. Upon 24 hours following transfer,
the recipient mice received Ad-OVA virus by SubQ or IV route.
Activation and proliferation of the OT-1 T cells in the liver,
spleen, and lymph nodes was monitored by CSFE dilution and T
cell activation marker expression at 36 and 48 hrs post virus
inoculation.
As Fig. 2A demonstrates, following SubQ virus administration,
proliferation of the adoptively transferred OT-1 T cells was
restricted primarily to the inguinal lymph nodes draining at the
Figure 2. IV adenovirus administration leads to systemic CD8
+ T cell proliferation. (A) CFSE labeled Thy1.1
+OT-1
+CD8
+ T cells (2610
6 cells
per mouse) were adoptively transferred into naı ¨ve Thy1.2
+ C57BL/6 mice. After 24 hours of adoptive transfer, the recipient mice were then infected
with 5610
8 PFU Ad-OVA via either SubQ or IV injection. At 36 and 48 hours p.i., the liver, spleen, Ig LN, and liver LN were isolated and the expression
of CD25 by proliferating Thy1.1
+CD8
+ T cells was analyzed by flow cytometry. The plots are gated on Thy1.1
+CD8
+ T cells. Data are representative of
three independent experiments. (B) Thy1.2
+ C57BL/6 mice were infected with 5610
8 PFU Ad-OVA via either SubQ or IV inoculation. At 48 hours p.i.,
liver, spleen, Ig LN, and liver LN cells were isolated and then incubated with 1610
5 naı ¨ve CFSE labeled Thy1.1
+OT-1
+CD8
+ T cells in vitro for 72 hours.
The plots are gated on Thy1.1
+CD8
+ T cells and the presence of dividing Thy1.1
+CD8
+ T cells was determined. Data are representative of two
independent experiments.
doi:10.1371/journal.pone.0007619.g002
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proliferating T cells upregulated expression of CD25. The onset of
T cell proliferation occurred between 36 and 48 hrs after virus
inoculation. This time frame for proliferation presumably reflects
the time required for uptake of virus by tissue antigen presenting
cells (APC) and subsequent migration of the APC to the draining
inguinal nodes for antigen presentation to naı ¨ve T cells. In addition,
there was minimal proliferation of T cells present in the liver, spleen
or non-draining lymph nodes over this 48 hrs time frame. Thus
following SubQ virus administration, viral antigen presentation was
restricted to the draining lymph nodes at the site of virus
inoculation. We confirmed this conclusion in companion experi-
ments where mononuclear cells were isolated from the liver, spleen,
and draining and non-draining lymph nodes at 48 hours following
SubQ Ad-OVA administration. These leukocytes were then co-
cultured in vitro for 3 days with CSFE-labeled naı ¨ve OT-1 T cells.
When cultured T cells were evaluated for activation/proliferation,
only mononuclear cells isolated from the draining inguinal lymph
nodes were able to trigger T cell proliferation in vitro (Fig. 2B).
When virus was delivered by IV route, by contrast, proliferating
T cells were detected in the liver, spleen and lymph node
compartments at 36 hours p.i. and proliferation proceeded over
the liver and the secondary lymphoid tissues with similar kinetics
over the succeeding 12 hours (Fig. 2A). This finding suggested that
after IV inoculation, virus was distributed to both the liver and
secondary lymphoid tissues. In keeping with this suggestion, we
found that mononuclear cells isolated from both liver and
secondary lymphoid organs could support the in vitro proliferation
of naı ¨ve OT-1 T cells (Fig. 2B). The in vivo analysis of the T cell
response to IV virus inoculation also revealed that while the
activation marker CD25 was significantly upregulated in T cell
responses within the secondary lymphoid organs, CD25 expression
was blunted/suppressed in OT-1 T cells responding in the liver
(Fig. 2B). Minor CD25
+CD8
+ T cell population appears at
48 hour possibly due to the migration of CD8
+ T cells generated
in the secondary lymphoid organs into the liver.
The above kinetic analysis suggested that following IV virus
administration, the liver could support the initial activation and
early proliferation of naı ¨ve antigen specific CD8
+ T cells.
However, we could not exclude the possibility that following IV
virus inoculation, CD8
+ T cells were activated in the secondary
lymphoid organs, i.e. spleen and lymph nodes, and subsequently
migrated to the liver. To further explore these alternatives, we first
examined transferred OT-1 T cells resident in the liver for the
expression of the early activation marker CD69 following IV or
SubQ administration of Ad-OVA virus. As Fig. 3A demonstrates,
upregulation of CD69 could be detected in the liver resident TCR
transgenic CD8
+ T cells as early as 4 hours following IV virus
administration. As expected, minimal upregulation of CD69 was
observed in liver resident OT-1 T cells up to 24 hours following
SubQ virus inoculation. Importantly, non-transgenic antigen-
nonspecific Thy1.2
+ recipient endogenous CD8
+ T cells present in
the liver demonstrated minimal upregulation of CD69, suggesting
that the upregulation of this molecule in the TCR transgenic T
cells was antigen driven and was not due to nonspecific
inflammatory stimuli in the liver associated with IV virus
administration.
To further elucidate the liver as the site for priming of naı ¨ve
CD8
+ T cells, we examined the impact of splenectomy on the
response of liver-resident OT-1 T cells to IV virus administration
in the adoptive transfer model. To further ensure that CD8
+ T
cells activated within the lymph node compartments were not
contributing to the pool of proliferating transgenic T cells in the
liver of splenectomized mice, this analysis was carried out in
splenectomized and sham splenectomized mice which received
monoclonal antibody (Mel-14) to L selectin (CD62L) one day prior
to adoptive transfer. This Mel-14 antibody inhibits the migration
of circulating naı ¨ve T cells into the lymph nodes and prevents T
cell activation there. As shown in Fig. 3B, the early proliferative
response of naı ¨ve CD8
+ T cells to viral antigen in the liver was
unaffected by splenectomy, suggesting that priming of naı ¨ve CD8
+
T cells can occur in the liver.
Figure 3. The liver supports CD8
+ T cell priming with rapid activation of antigen-specific CD8
+ T cells. (A) To determine how early CD8
+
T cells are activated in the liver, 4610
6 Thy1.1
+OT-1
+CD8
+ T cells were adoptively transferred into naı ¨ve Thy1.2
+ C57BL/6 mice and then mice were
infected with 5610
8 PFU Ad-OVA via either SubQ or IV administration one day later. At 4, 6, and 24 hours p.i., liver and Ig LN cells were isolated and
the expression of CD69 by antigen specific CD8
+ T cells (Thy1.1
+OT-1
+CD8
+ gated) and endogenous CD8
+ T cells (Thy1.1
2CD8
+ T cells) was analyzed
by flow cytometry. The 0 hour data points indicate control mice that received PBS administration. Data are representative of at least two
independent experiments. (B) 2610
6 CFSE labeled Thy1.1
+OT-1
+CD8
+ T cells were adoptively transferred into either splenectomized or sham control
Thy1.2
+ C57BL/6 mice treated with Mel-14 Ab one day prior to adoptive transfer. The recipient mice were then infected with 5610
8 PFU Ad-OVA via
IV administration one day later after adoptive transfer. At 48 hours p.i., liver, spleen, and IgLN cells were isolated and the expression of CD25 by
proliferating Thy1.1
+CD8
+ T cells was analyzed by flow cytometry. The plots are gated on Thy1.1
+CD8
+ T cells and the numbers represent the
percentage of cells within the indicated gates.
doi:10.1371/journal.pone.0007619.g003
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+ T Cells Activated in the Liver Lead to Defective
Differentiation of Effector T Cells
Theabovefindingssuggested thatnaı ¨veCD8
+Tcellsactivated in
the liver are capable of undergoing initial proliferation at this site.
However, the expression of at least one marker of T cell activation,
i.e. CD25, appeared to be defective in naive T cells activated within
the liver environment (Fig. 2, 3). To further explore the impact of T
cell induction within the liver environment on CD8
+ T cell
differentiation, we examined the expression of two important CD8
+
T cell effector molecules, i.e. IFN-c and granzyme B, in transferred
OT-1 T cells in the liver, spleen and inguinal lymph nodes
respondingtoSubQorIVAd-OVAvirusadministration.AsFig.4A
demonstrates, activation/proliferation of naı ¨ve T cells following
SubQ virus administration was restricted to the inguinal nodes and
the proliferating T cells were fully capable of expressing IFN-c and
granzyme B. Following IV virus administration, IFN-c and
granzyme B production were detected in responding T cells
stimulated in the spleen and lymph nodes (Fig. 4A). By contrast,
naı ¨ve T cells activated by virus within the liver failed to upregulate
expression of either of these T cell effector molecules (Fig. 4A).
When the influence of splenic and lymph nodes derived CD8
+ T
cells are removed from these experiments using splenectomized and
Mel-14 Ab treated mice, we similarly observe that liver primed
CD8
+ T cells do not differentiate into potent effectors (Fig. 4B). In
companion studies, we evaluated the expression of several other cell
surface activation markers. We found that, in contrast to CD8
+ T
cells activated in the spleen or lymph nodes, the majority of naı ¨ve
CD8
+ T cells activated within the liver failed to down regulate
CD62L (data not shown).
As demonstrated above (Fig. 1A), viral antigen administration
by IV route results in a diminished number of antigen-specific tet
+
CD8
+ T cells at days 7 and 14 p.i. compared to SubQ virus
inoculation where there is a substantial accumulation of antigen-
specific tet
+ CD8
+ T cells in the liver. While this discrepancy
would most easily argue for a defect in the activation/proliferation
of responding CD8
+ T cells following IV virus administration, our
observations on the early response of CD8
+ T cells in the liver (e.g.
Fig. 2 and 3) do not suggest such a defect. Rather the data suggest
that IV virus administration and liver priming likely result in a
defect in CD8
+ T cell differentiation into effector cells. To further
examine the basis for this potential discrepancy, we analyzed the
response of Thy1.1
+ transgenic CD8
+ T cells transferred into
congenic Thy1.2
+ recipients at day 7 after administration of virus
by SubQ or IV route. Consistent with our earlier findings in
Fig. 1A, a large fraction of transgenic Thy1.1
+CD8
+ T cells
capable of responding to antigenic stimulation with IFN-c
production accumulated in the liver on day 7 following SubQ
virus delivery. More importantly, a corresponding large number of
Thy1.1
+ transgenic T cells accumulated in the liver following IV
virus delivery but these T cells, like activated CD8
+ T cells
analyzed at early time points after antigenic stimulation in the liver
(Fig. 2, 3), failed to produce IFN-c (Fig. 5A). In addition, the
observed CD8
+ T cell dysfunction was independent of viral doses
administered into mice (Fig. 5B). It suggests that the impaired
CD8
+ T cell function as seen in the IV virus delivery is not due to
the high dose of viral antigen administered into the liver.
We next examined whether CD8
+ T cell dysfunction is
associated with the upregulation of PD-1 expression. Functionally
exhausted CD8
+ T cell populations and CD8
+ T cell death in the
liver impair viral clearance during persistent infections including
HCV and HBV [33]. The PD-1/B7-H1 inhibitory pathway has
been demonstrated to play an important role in the regulation of
anti-viral immune responses in the liver [34,35,36,37,38]. To this
end, Thy1.1
+OT-1
+CD8
+ T cells were adoptively transferred into
naı ¨ve Thy1.2
+ C57BL/6 mice that were then infected with Ad-
OVA via either SubQ or IV immunization route. At day 7 post IV
infection, the majority of OVA-specific CD8
+ T cells in the liver
express PD-1 while PD-1 is not expressed by OVA-specific CD8
+
T cells that migrate to the liver following SubQ immunization
(Fig. 5C). In addition, antigen-specific and bulk intrahepatic CD8
+
T cells generated during IV adenovirus infection express elevated
levels of active caspase-3, which serves as an indicator of apoptosis
while the liver can support viable antigen-specific CD8
+ T cells
when virus is delivered to other peripheral sites (data not shown).
However, treatment of anti-B7-H1 Ab prior to adenovirus
infection did not restore the IFN-c production by CD8
+ T cells
in the liver although it slightly increased the number of IFN-
c
+CD8
+ T cells in the spleen compared to mice treated with
control Ab (Fig. 5D). It suggests that the PD-1 negative
costimulatory pathway might not be directly involved in the
induction of CD8
+ T cells with impaired function in the liver.
Antigen Dependence of CD8
+ T Cell Dysfunction in the
Liver Environment
Our observations to this point strongly suggest that the liver is a
major site of naı ¨ve CD8
+ T cell activation when hepatotropic
antigen such as rAd is administered by IV route. Naı ¨ve CD8
+ T
cell priming in the liver results in the alteration of CD8
+ T cell
differentiation and expression of effector activities. However,
activated CD8
+ T cells, which accumulate in the liver following
SubQ virus administration, do not exhibit a dysfunctional
phenotype. Furthermore, IV virus delivery does result in the
activation of CD8
+ T cells within secondary lymphoid organs and
the activated CD8
+ T cells, which remain in that site, appear to be
functionally normal (Fig. 2A). Yet if these CD8
+ T cells within
secondary lymphoid tissues, which have been activated in response
to IV virus administration and then migrate to the liver, they
would appear to also acquire a dysfunctional phenotype.
We therefore wanted to determine if, in the liver environment,
previously activated functional effector CD8
+ T cells can be
rendered dysfunctional and whether this process was dependent on
specific antigen recognition within the liver. To this end, we
transferred naı ¨ve Thy1.1
+ OT-1 CD8
+ T cells into congenic
Thy1.2
+ recipient animals and infected the recipient animals with
Ad-OVA virus by SubQ route. Four days after infection, we isolated
Thy1.1
+ T cells from the secondary lymphoid tissues of the recipient
mice and then transferred these activated CD8
+ T cells into Thy1.2
+
recipient mice, which had been infected with either Ad-OVA or Ad-
LacZ by IV route (Fig. 6A). By employing this strategy, we
determined whether the effector response of fully activated effector
CD8
+ T cells could be suppressed within the liver environment and
whether specific antigen recognition (mediated by IV Ad-OVA
administration) or simply acute liver inflammation (orchestrated by
IV Ad-LacZ administration) was required to suppress the activated
effector CD8
+ T cells. Activated Thy1.1
+ OT-1 CD8
+ Tc e l l s
adoptively transferred into uninfected recipient mice served as a
background control. Upon 24 hours after cell transfer, the Thy1.1
+
OT-1CD8
+Tcellswereisolatedfromtheliversoftherecipientmice
and were analyzed for specific tetramer staining directly ex vivo and
for the expression of IFN-c and TNF-a in response to specific
antigen stimulation by the in vitro intracellular cytokine assay.
The OT-1 T cells isolated from the control (uninfected) livers and
from the inflamed livers of mice infected IV with Ad-LacZ virus
uniformly bound specific tetramer and expressed IFN-c and TNF-a
in response to peptide stimulation. In contrast, T cells isolated from
the livers of mice with the expression of specific antigen by Ad-OVA
infection exhibited reduced tetramer staining and defective expres-
sion of proinflammatory cytokines compared to the inflammation
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+ T cells do not differentiate into competent effectors. (A) 2610
6 CFSE labeled Thy1.1
+OT-1
+CD8
+ T cells were
adoptively transferred into naı ¨ve Thy1.2
+ C57BL/6 mice and then mice were infected with 5610
8 PFU Ad-OVA via either SubQ or IV immunization one
day later. At 48 hours p.i., liver, spleen, and Ig LN were isolated and leukocytes were stimulated in the presence of OVA peptide and monensin for
5 hours. The ability of dividing Thy1.1
+CD8
+ T cells to produce IFN-c and granzyme-B (GrB) following peptide restimulation was assessed using flow
cytometry. The plots are gated on Thy1.1
+CD8
+ T cells. (B) 2610
6 CFSE labeled Thy1.1
+OT-1
+CD8
+ T cells were adoptively transferred into either
splenectomized or sham control Thy1.2
+ C57BL/6 mice that were treated a day before with Mel-14 Ab. Mice were then infected with 5610
8 PFU Ad-
OVA via IV administration one day later. At 48 hours p.i., liver and spleen cells were isolated and then restimulated directly ex vivo with OVA peptide
for 5 hours in the presence of monensin. The production of IFN-c and granzyme-B by proliferating Thy1.1
+CD8
+ T cells was analyzed by flow
cytometry. The plots are gated on Thy1.1
+CD8
+ T cells. Data are representative of at least two independent experiments.
doi:10.1371/journal.pone.0007619.g004
Dysfunctional T Cell in Liver
PLoS ONE | www.plosone.org 8 October 2009 | Volume 4 | Issue 10 | e7619only and control groups (Fig. 6B, 6C). These results indicate that the
l i v e re n v i r o n m e n tp e rs eo re v e nt h ei n f l a m e dl i v e re n v i r o n m e n t
resulting from virus infection is not sufficient to induce an abortive
CD8
+ T cell response. Rather, the development of this defective
response requires specific antigen recognition within the liver.
Antigen Presentation by Liver Parenchyma Cells Induces
Suboptimal Differentiation of CD8
+ T Cells
Our observations to this point suggest that the liver can serve as
a site for the induction of CD8
+ T cell responses outside the
secondary lymphoid tissues. However, naı ¨ve T cell activation by
antigen within the liver or the encounter of previously activated
CD8
+ T cells with antigen displayed in the liver results in the
dysregulation of CD8
+ T cell effector function. Although the liver
contains a variety of CD45
+ cell types which could serve as APC
for naı ¨ve or activated antigen specific CD8
+ T cells, hepatotropic
agents like rAd virus may preferentially infect and express antigen
in hepatocytes [39,40,41]. This consideration prompted us to
inquire whether T cell activation in the liver leading to
dysregulation of effector function of the activated CD8
+ T cells
Figure 5. IV adenovirus infection causes a robust defect in CD8
+ T cell effector function with elevated PD-1 expression in the liver.
(A, B) 0.5610
6 Thy1.1
+OT-1
+CD8
+ T cells were adoptively transferred into naı ¨ve Thy1.2
+ C57BL/6 mice. These mice were allowed to rest for one day
and were then infected with 5610
8 PFU Ad-OVA via either SubQ or IV injection (A) or 5610
8,5 610
7,5 610
6 PFU Ad-OVA via IV injection (B). At day 7
p.i., liver leukocytes were isolated and then restimulated directly ex vivo with PMA/ionomycin (A) or OVA peptide in the presence of monensin (B) for
5 hours. The plots are gated on live cells and the numbers represent the percentage of cells within the indicated gates. (C) 2610
6 Thy1.1
+OT-1
+CD8
+
T cells were adoptively transferred into naı ¨ve Thy1.2
+ C57BL/6 mice. These mice were allowed to rest for one day and then they were infected with
5610
8 PFU Ad-OVA via either SubQ or IV injection. At day 7 p.i., liver leukocytes were isolated and the percentage of Thy1.1
+CD8
+ T cells expressing
PD-1 was determined. The expression of PD-1 by CD8
+ T cells in the spleen, lung, and liver following 5610
8 PFU Ad-OVA IV infection was also
evaluated (right histogram). Both of the plots are gated on CD8
+ T cells. Data are representative of two independent experiments (n=2/group). (D)
Effect of PD-1 blockade on the liver primed CD8
+ T cell effector activity. 2610
6 CFSE labeled Thy1.1
+OT-1
+CD8
+ T cells were adoptively transferred
into Thy1.2
+C57BL/6 mice treated with anti-B7-H1 or control antibody (200 ug per mouse) one day prior to adoptive transfer. The recipient mice were
infected with 5610
8 PFU Ad-OVA via IV administration one day later. At 48 hours p.i., liver and spleen cells were isolated and then restimulated
directly ex vivo with OVA peptide for 5 hours in the presence of monensin. The production of IFN-c by proliferating Thy1.1
+CD8
+ T cells was analyzed
by flow cytometry and the plots are gated on Thy1.1
+CD8
+ T cells.
doi:10.1371/journal.pone.0007619.g005
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displayed on liver parenchymal cells. To explore this possibility,
we constructed bone marrow chimeras in which lethally irradiated
C57BL/6 mice were reconstituted with allogeneic BALB/c bone
marrow. Following reconstitution, these animals contain hemato-
poietic cells expressing H-2
d haplotype MHC class I molecules and
liver parenchyma expressing the H-2
b haplotype MHC class I
molecules. Reconstitution of bone marrow chimera was verified by
flow cytometry analysis: the intrahepatic CD11b
+CD45
+ cells
isolated from Balb/cRB6 chimeras express high levels (.95%) of
H2-K
d, and only a small fraction (,4%) express H2-K
b at levels
that are slightly above background. In these mice, only liver
parenchyma cells should be able to present OVA257-264 epitope to
H2-K
b-restricted OT-1
+CD8
+ T cells during Ad-OVA infection.
In contrast, the bone marrow derived APCs in the Balb/cRB6
mice chimera mice should express only H2-K
d class I molecules
and be unable to present cognate OVA antigen to OT-1
+CD8
+ T
cells during Ad-OVA infection.
To examine the ability of liver parenchyma cells to present
antigen and induce CD8
+ T cell proliferation, CFSE labeled
Thy1.1
+OT-1
+CD8
+ T cells were adoptively transferred into
Balb/cRB6 and control B6RB6 mice that were then infected
with Ad-OVA by IV immunization route. At 2 days p.i.,
Thy1.1
+OT-1
+CD8
+ T cells had proliferated to similar levels in
both Balb/cRB6 and control B6RB6 mice (Fig. 7A). Thus liver
parenchyma cells presenting foreign antigen are able to induce the
proliferation of naı ¨ve CD8
+ T cells. Furthermore, CD8
+ T cells
primed by the antigen-presenting liver parenchyma cells fail to
differentiate into competent effectors. The dividing T cells do not
acquire the ability to produce IFN-c or GrB following antigen
recognition on liver parenchyma cells (Fig. 7B). This suggests that
antigen presentation by liver parenchyma cells results in
incomplete differentiation of CD8
+ T cells.
Discussion
In this report, we examined the impact of foreign (viral) antigen
expression and the induction of adaptive immune CD8
+ T cell
response in the liver on the subsequent development of the
magnitude and quality of the CD8
+ effector T cell response. To
achieve the liver priming of naı ¨ve T cells, we made use of the fact
that the hepatotropic adenovirus would preferentially localize and
express antigen in the liver when delivered by the IV route. We
observed that, in contrast to induction of antiviral CD8
+ T cell
responses and vigorous effector CD8
+ T cell responses in
secondary lymphoid tissues such as lymph nodes and spleen by
Figure 6. TCR engagement is required for impairment of CD8
+ T cell effector function in the liver. (A) 5610
6 Thy1.1
+OT-1
+CD8
+ T cells
were adoptively transferred into Thy1.2
+ C57BL/6 mice that were then infected with 5610
8 PFU Ad-OVA via SubQ injection one day later. On day 4
p.i., spleen and IgLN cells were isolated and Thy1.1
+ cells were purified. 2610
6 Thy1.1
+OT-1
+CD8
+ T cells from day 4 SubQ primed mice were
adoptively transferred into Thy1.2
+ mice that were infected 4 days earlier via IV injection with either 5610
8 PFU Ad-LacZ (inflammation group) or
5610
8 PFU Ad-OVA (Ag+inflammation group). As a control, 5610
6 Thy1.1
+OT-1
+CD8
+ T cells from day 4 SubQ primed mice were adoptively
transferred into naı ¨ve Thy1.2
+ mice (control group). (B) At 24 hours post adoptive transfer of SubQ primed effectors, the expression of OVA tetramer
and CD69 by intrahepatic Thy1.1
+OT-1
+CD8
+ T cells was analyzed by flow cytometry. The plots are gated on CD8
+ T cells. The numbers indicate the
percentage of adoptively transferred cells positive for OVA tetramer or CD69. (C) Liver cells were also restimulated directly ex vivo with OVA peptide
for 5 hours in the presence of monensin. The numbers indicate the percentage of Thy1.1
+OT-1
+CD8
+ T cells that produce IFN-c or TNF-a following
peptide restimulation. The plots are gated on Thy1.1
+CD8
+ T cells. The data are representative of three independent experiments.
doi:10.1371/journal.pone.0007619.g006
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+ T cell responses in
the liver results in a defect in the differentiation of responding
CD8
+ T cells into pro-inflammatory cytokine producing cytolytic
effector T cells. In addition, when conventional effector CD8
+ T
cells generated within secondary lymphoid tissues migrated to the
target antigen-expressing liver compartment, they also acquire a
dysfunctional phenotype resulting in the diminished capacity to
express proinflammatory cytokines/cytolytic effector molecules.
Finally, studies employing bone marrow chimera mice suggest that
the defective effector T cell phenotype exhibited by responding
CD8
+ T cells might be dependent on recognition of foreign
antigen displayed on CD45
2 hepatic parenchyma cells.
The central finding in this report is that intrahepatic stimulation
of naı ¨ve antigen specific CD8
+ T cells results in activation and
proliferation of the T cells but a failure to express antiviral effector
activities, e.g. IFN-c and granzyme B, characteristic of mature
CD8
+ effector T cells. To some degree, this phenotype parallels the
functional ‘‘exhaustion’’ of virus-specific CD8
+ T cells reported in
chronic liver infections with hepatotropic viruses such as HBV and
HCV [42,43,44,45]. In those chronic persistent human infections,
the apparent exhaustion of effector T cells along with deletion of
effector T cells is believed to be linked to the diminished antiviral
effector activity and persistence of infection with these agents.
Although it has not been examined in this report, the defect in
effectoractivityexhibited byCD8
+ T cellsgenerated intheliver also
appears to adversely affect virus/antigen clearance since antigen
(e.g. bgal enzymatic activity) elimination from the site of primary
virus inoculation is delayed when the liver is the site of initial
infection (J.R. Lukens, unpublished observations). However, the
dysfunctional intrahepatic effector T cell response observed in this
report is not likely to be specific to recombinant adenovirus because
T cells generated to adenovirusinfection at other peripheral sites via
subcutaneous and intranasal inoculation do not exhibit a similar T
cell defect. Furthermore, the recombinant adenovirus with deletion
of immunomodulatory proteins, E1, E3, was used in our studies to
avoid the interference of host immunity.
Prolonged TCR downregulation has been previously observed
as a property of anergic T cells maintained in vivo under conditions
of high-level antigen persistence [46,47,48]. This is likely
associated with high dose of virus administration. However,
activated CD8
+ T cells from the livers of mice receiving IV rAd
infection also fail to produce IFN-c or granzyme B in response to
the in vitro stimulation with PMA/ionomycin (J.R. Lukens,
unpublished observations). Importantly, the impairment of CD8
+
T cell effector activity by IV rAd infection was independent of viral
doses administered into mice. In addition, the defect in IFN-c and
granzyme B production and the associated dysfunctional pheno-
type observed among the CD8
+ T cells activated in liver did not
attribute to the failure of these T cells to recognize antigen because
of TCR downregulation. At present, it is yet to be identified the
precise mechanism(s) involved in the induction of dysfunctional
CD8
+ T cells primed in the liver.
It is likewise noteworthy that the liver primed activated CD8
+ T
cells have diminished expression of CD25 and increased
Figure 7. Antigen presentation by liver parenchyma cells induces suboptimal differentiation of CD8
+ T cells. 2610
6 CFSE labeled
Thy1.1
+OT-1
+CD8
+ T cells were adoptively transferred into naı ¨ve Thy1.2
+ C57BL/6 mice reconstituted with BalbC or C57BL/6 bone marrow and then
the recipient mice were infected with 5610
8 PFU Ad-OVA via IV injection one day later. (A) At 48 hours p.i., liver cells were isolated and the
proliferative response of OVA-specific CD8
+ T cells was evaluated. The plots are gated on Thy1.1
+CD8
+ T cells. (B) The expression of CD25 and OVA
tetramer by proliferating OVA-specific CD8
+ was evaluated directly ex vivo. The ability of dividing Thy1.1
+CD8
+ T cells to produce IFN-c, and
granzyme-B following peptide restimulation was assessed using flow cytometry. The plots are gated on Thy1.1
+CD8
+ T cells. Data are representative
of two independent experiments.
doi:10.1371/journal.pone.0007619.g007
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inhibitory receptors, we found that the liver primed and localized
activated CD8
+ T cells display elevated levels of the inhibitory
receptor PD-1 (Fig. 5C). Although the expression of PD-1 has been
linked to the development of the ‘‘exhausted’’ phenotype of CD8
+
T effector cells and appears to play a role in immune dysregulation
mediated by HCV-core protein expressed in the hepatocytes via
rAd in this murine model [30], we have been unable to reverse the
dysfunctional phenotype of liver primed CD8
+ T cell effectors by
blocking PD-1/PD-1 ligand interaction in vivo (Fig. 5D). These
findings do not exclude a possible role of PD-1 in the development
of the defective effector cell phenotype as recent evidence suggests
that blocking of more than one inhibitory receptor on activated T
cells may be necessary to restore functionality [49].
The mechanism by which CD8
+ T cell ‘‘priming’’ in the liver
leads to dysfunctional effector cells remains to be determined. As
noted above, the liver is recognized as a tolerogenic environment
and many factors, e.g. IL-10 expression, have been implicated
mechanistically in the establishment and maintenance of this
tolerogenic state. Our findings reported here are, to our
knowledge, the first to formally demonstrate that the induction
of adaptive immune CD8
+ T cell response within the liver
(presumably through presentation of antigen to naı ¨ve T cells by
liver parenchyma cells) results in the development of a defective
effector T cell response. The finding that CD8
+ T cells activated
within secondary lymphoid organs (and therefore undergoing the
normal sequence of activation and differentiation into effector
cells) are also rendered defective upon specific recognition of
antigen displayed by hepatic cells further suggest that the this
environment and cognate recognition of antigen by CD8
+ T cells
within the liver profoundly influence the activation/differentiation
state of the effector CD8
+ T cells.
Collectively, our results provide evidence that the liver tissue
can support the de novo activation of anti-viral naı ¨ve CD8
+ T cells
but with incomplete differentiation, and that intrahepatic
recognition of antigen by activated CD8
+ T cells results in
dysregulated effector activities. Our study underscores the
importance of the liver environment in the generation and control
of effector function of the virus-specific CD8
+ T cells. Interplay
between this distinct intrahepatic microenvironment and immune-
dysregulatory pathogenic components such as core protein from
HCV [50,51] could lead to the immune evasion by hepatotropic
pathogens and promote the establishment of a chronic infection in
the liver. Further investigation is warranted to examine in
particular the nature of antigen presenting cells and cellular
factors that regulate the intrahepatic T cell activation as well as
quality of effector CD8
+ T cell activities at the site of infection.
Such information will in turn allow us to manipulate antigen-
specific CD8
+ T cells for a better control of chronic hepatic
infections in the human.
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